SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia - PubMed (original) (raw)
. 2001 Feb;296(2):312-21.
E A Irving, A M Ray, J C Lee, S Kassis, S Kumar, A M Badger, R F White, M J McVey, J J Legos, J A Erhardt, A H Nelson, E H Ohlstein, A J Hunter, K Ward, B R Smith, J L Adams, A A Parsons
Affiliations
- PMID: 11160612
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia
F C Barone et al. J Pharmacol Exp Ther. 2001 Feb.
Abstract
The stress-activated mitogen-activated protein kinase (MAPK) p38 has been linked to the production of inflammatory cytokines/mediators/inflammation and death/apoptosis following cell stress. In these studies, a second-generation p38 MAPK inhibitor, SB 239063 (IC(50) = 44 nM), was found to exhibit improved kinase selectivity and increased cellular (3-fold) and in vivo (3- to 10-fold) activity over first-generation inhibitors. Oral SB 239063 inhibited lipopolysaccharide-induced plasma tumor necrosis factor production (IC(50) = 2.6 mg/kg) and reduced adjuvant-induced arthritis (51% at 10 mg/kg) in rats. SB 239063 reduced infarct volume (48%) and neurological deficits (42%) when administered orally (15 mg/kg, b.i.d.) before moderate stroke. Intravenous SB 239063 exhibited a clearance of 34 ml/min/kg, a volume of distribution of 3 l/kg, and a plasma half-life of 75 min. An i.v. dosing regimen that provided effective plasma concentrations of 0.38, 0.75, or 1.5 microg/ml (i.e., begun 15 min poststroke and continuing over the initial 6-h p38 activation period) was used. Significant and dose-proportional brain penetration of SB 239063 was demonstrated during these infusion periods. In both moderate and severe stroke, intravenous SB 239063 produced a maximum reduction of infarct size by 41 and 27% and neurological deficits by 35 and 33%, respectively. No effects of the drug were observed on cerebral perfusion, hemodynamics, or body temperature. Direct neuroprotective effects from oxygen and glucose deprivation were also demonstrated in organotypic cultures of rat brain tissue. This robust in vitro and in vivo SB 239063-induced neuroprotection emphasizes the potential role of MAPK pathways in ischemic stroke and also suggests that p38 inhibition warrants further study, including protection in other models of nervous system injury and neurodegeneration.
Similar articles
- Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia.
Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, Parsons AA. Barone FC, et al. Med Res Rev. 2001 Mar;21(2):129-45. doi: 10.1002/1098-1128(200103)21:2<129::aid-med1003>3.0.co;2-h. Med Res Rev. 2001. PMID: 11223862 Review. - SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia.
Legos JJ, Erhardt JA, White RF, Lenhard SC, Chandra S, Parsons AA, Tuma RF, Barone FC. Legos JJ, et al. Brain Res. 2001 Feb 16;892(1):70-7. doi: 10.1016/s0006-8993(00)03228-5. Brain Res. 2001. PMID: 11172750 - Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death.
Barancik M, Htun P, Strohm C, Kilian S, Schaper W. Barancik M, et al. J Cardiovasc Pharmacol. 2000 Mar;35(3):474-83. doi: 10.1097/00005344-200003000-00019. J Cardiovasc Pharmacol. 2000. PMID: 10710135 - SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE. Underwood DC, et al. J Pharmacol Exp Ther. 2000 Apr;293(1):281-8. J Pharmacol Exp Ther. 2000. PMID: 10734180 - Therapeutic potential of anti-inflammatory drugs in focal stroke.
Barone FC, Parsons AA. Barone FC, et al. Expert Opin Investig Drugs. 2000 Oct;9(10):2281-306. doi: 10.1517/13543784.9.10.2281. Expert Opin Investig Drugs. 2000. PMID: 11060807 Review.
Cited by
- The P38MAPK/ATF2 signaling pathway is involved in PND in mice.
Zhu M, Long S, Tao Y, Zhang Z, Zhou Z, Wang X, Chen W. Zhu M, et al. Exp Brain Res. 2024 Jan;242(1):109-121. doi: 10.1007/s00221-023-06730-6. Epub 2023 Nov 16. Exp Brain Res. 2024. PMID: 37973625 Free PMC article. - The Relationship of Astrocytes and Microglia with Different Stages of Ischemic Stroke.
Liang Z, Lou Y, Hao Y, Li H, Feng J, Liu S. Liang Z, et al. Curr Neuropharmacol. 2023;21(12):2465-2480. doi: 10.2174/1570159X21666230718104634. Curr Neuropharmacol. 2023. PMID: 37464832 Free PMC article. Review. - An overview of hyperbaric oxygen preconditioning against ischemic stroke.
Wu X, You J, Chen X, Zhou M, Ma H, Zhang T, Huang C. Wu X, et al. Metab Brain Dis. 2023 Mar;38(3):855-872. doi: 10.1007/s11011-023-01165-y. Epub 2023 Feb 2. Metab Brain Dis. 2023. PMID: 36729260 Free PMC article. Review. - Strategies for Improving Photodynamic Therapy Through Pharmacological Modulation of the Immediate Early Stress Response.
de Klerk DJ, de Keijzer MJ, Dias LM, Heemskerk J, de Haan LR, Kleijn TG, Franchi LP, Heger M; Photodynamic Therapy Study Group. de Klerk DJ, et al. Methods Mol Biol. 2022;2451:405-480. doi: 10.1007/978-1-0716-2099-1_20. Methods Mol Biol. 2022. PMID: 35505025 Review. - Activation of α7 nicotinic acetylcholine receptor ameliorates HIV-associated neurology and neuropathology.
Zhao X, Wilson K, Uteshev V, He JJ. Zhao X, et al. Brain. 2021 Dec 16;144(11):3355-3370. doi: 10.1093/brain/awab251. Brain. 2021. PMID: 34196664 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical